Supply constraints loom as Regeneron reports positive data on COVID-19 mAb

Days before FDA is expected to decide about their emergency use authorization requests, Regeneron released new data confirming the efficacy of its COVID-19 mAb cocktail and Lilly announced that the U.S. government has contracted to purchase its mAb.

The cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) met the study’s first nine endpoints. In addition to meeting virologic endpoints, REGN-COV2 reduced COVID-19 related medical visits by 57% through day 29 overall and 72% in patients with one or more risk factor...